Johnson & Johnson (NYSE:JNJ) Shares Sold by Blooom Inc.

Blooom Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 8,733 shares of the company’s stock after selling 62 shares during the quarter. Johnson & Johnson comprises approximately 0.6% of Blooom Inc.’s investment portfolio, making the stock its 27th biggest holding. Blooom Inc.’s holdings in Johnson & Johnson were worth $318,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in JNJ. Red Wave Investments LLC raised its position in shares of Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock worth $530,000 after purchasing an additional 59 shares during the period. Argus Investors Counsel Inc. raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock worth $1,941,000 after purchasing an additional 61 shares during the period. Alta Capital Management LLC raised its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after purchasing an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC raised its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after purchasing an additional 62 shares during the period. Finally, Mason & Associates Inc raised its position in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after purchasing an additional 62 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 in the last three months. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $168.74 on Monday. The stock has a fifty day moving average price of $176.14 and a two-hundred day moving average price of $171.20. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a market cap of $441.17 billion, a P/E ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Bank of America dropped their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Sanford C. Bernstein lowered their target price on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. SVB Leerink lowered their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday. Barclays assumed coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price on the stock. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.